Effect of Conversion From Intravenous to Oral Administration on Cyclosporine Exposure in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation

A conversion ratio of 1:3 was found to be more appropriate for pediatric allo-HSCT recipients when switching cyclosporine from intravenous to oral administration. Children younger than 3 years old or with moderately increased transaminases had significant lower cyclosporine bioavailability. These results can assist in an individualized approach for patients undergoing cyclosporine formulation switching.